Werewolf Therapeutics develops conditionally activated proinflammatory immune modulators, known as INDUKINE™ molecules, which are systemically administered in an inactive form and activated selectively within the tumor microenvironment. This approach targets the challenge of off-target effects in immunotherapy, enhancing the immune response against cancer while minimizing damage to healthy tissues.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Systemic immunotherapy often causes off-target effects, damaging healthy tissues while attempting to stimulate an immune response against cancer. This lack of specificity limits the effectiveness and tolerability of many immuno-oncology treatments.
Solution
Werewolf Therapeutics is developing INDUKINE™ molecules, a class of conditionally activated proinflammatory immune modulators designed to enhance the body’s immune response to cancer while minimizing off-target toxicity. These molecules are administered systemically in an inactive form and are engineered to selectively activate within the tumor microenvironment, delivering the full biological potency of cytokines directly to the tumor. The company's PREDATOR™ protein engineering technology allows for the design and engineering of targeted immuno-oncology biotherapeutics. This approach aims to improve the therapeutic window of immunotherapies by focusing the immune response specifically on the tumor.
Target Audience
The primary target audience includes cancer patients and healthcare providers seeking more effective and tolerable immuno-oncology therapies.
Features
- INDUKINE™ molecules: Systemically administered, conditionally activated proinflammatory immune modulators.
- PREDATOR™ protein engineering technology: Proprietary platform for designing targeted biotherapeutics.
- Tumor microenvironment activation: Molecules are engineered to selectively activate within the tumor.
- Enhanced immune response: Designed to unleash validated proinflammatory mechanisms on tumors.
- Reduced off-target effects: Prevents unwanted side effects on non-target tissue.